The widely dispersed health system is integrating the Congenica platform into its clinical and research workflows to uncover genetic bases for rare conditions.
Under their 10-year partnership, IBM will install an early instance of its Quantum System One at Cleveland Clinic to promote AI-driven life sciences discovery.
The method, which uses a metabolic marker called hexokinase-2, could be developed to predict cancer patient prognosis and determine progression-free survival.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
German bioinformatics startup 4HF Biotec targets early-stage biotech development with technology to predict drug sensitivity based on tumor genetic profiles.
The two California firms are linking their bioinformatics platforms in hopes of accelerating biomarker and drug discovery processes for pharma companies.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
